← 產業報告目錄

Mice Model Market by Model Type (Inbred, Outbred, Hybrid), Service (Breeding, Rederivation), Application (Personalized Medicine), Technology (Microinjection, CRISPR/Cas9), Therapeutic Area (Oncology, Neurology), End User (CROs) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-08-12頁數 446報告編號 BT2192

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The mice model market is projected to reach USD 2.74 billion by 2030 from USD 1.70 billion in 2025, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by several factors, such as rising adoption of mice models in preclinical studies due to genetic & physiological versatility; the increasing demand for mouse clinical trials (MCTs); the rising demand for personalized medicine in oncology; and advancements in genetic engineering. Utilization of CRISPR in biomedical research and the increasing demand for disease-specific models are also expected to contribute to market growth during the forecast period. By model type, the inbred mice segment accounted for the largest share of the market in 2024. The market is segmented by model type into inbred mice, genetically engineered mice, hybrid/congenic mice, and outbred mice. In 2024, the inbred mice segment accounted for the largest share of the mice model market. The large share of the inbred mice segment is attributed to the ability of inbred strains to provide genetic uniformity for preclinical studies, standardized breeding protocols that enable scalable production, and supply chains that support continuous availability. Regulatory frameworks at national and international levels recognize inbred strains as reference models for efficacy and safety assessment, and centralized breeding facilities implement quality control measures to maintain strain integrity. Adoption of inbred mice spans pharmaceutical and biotechnology companies and academic and government research institutions, where controlled genetic backgrounds reduce experimental variability. By application, the drug discovery & development segment accounted for the largest share of the market in 2024. The mice model market is segmented into drug discovery & development, research applications, and personalized medicine. In 2024, the drug discovery & development segment accounted for the largest share of the market. Mouse models are deployed in target validation assays to confirm the relevance of molecular targets, in lead optimization studies to compare pharmacodynamic profiles, and in efficacy evaluations to measure treatment responses under controlled conditions. Safety pharmacology protocols—cardiovascular, respiratory, and central nervous system endpoints—rely on telemetry recordings and behavioral assays conducted in mice. At the same time, reproductive and developmental toxicity assessments use timed-pregnancy protocols to determine embryonic viability and teratogenic risk. Histopathological examinations and clinical chemistry analyses of tissue samples support regulatory submissions, and omics profiling (transcriptomics, proteomics, metabolomics) informs dose selection and mechanism-of-action studies. Service providers integrate these applications into end-to-end workflows for end users. Combined, these integrated applications ensure the dominance of drug discovery & development applications in the mice model market. By region, North America accounted for the largest share of the mice model market in 2024. In 2024, North America accounted for the largest share of the mice model market due to the concentration of major contract research organizations and breeding suppliers, government and private funding mechanisms, and a regulatory environment emphasizing standardized preclinical practices. The key market players, such as Charles River Laboratories (US), The Jackson Laboratory (US), and Inotiv (US), have their presence in the region, thus ensuring regional supply and technical support. Public funding agencies such as the National Institutes of Health (NIH) allocate substantial budgets to basic & translational research, while pharmaceutical & biotechnology companies commit a significant portion of R&D expenditure to preclinical in vivo models. Academic research institutions and specialized contract research organizations leverage this infrastructure and funding landscape to conduct target validation, toxicology, and efficacy studies, reinforcing North America’s large share in the global mice model market. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40% • By Designation: C-level Executives - 55%, Directors- 20%, and Others- 25% • By Region: North America -45%, Europe - 20%, the Asia Pacific -20%, Latin America -10%, the Middle East- 3%, and Africa-2% Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), JSR Corporation (Japan), Biocytogen (China), TRANS GENIC INC. (Japan) Harbour BioMed (China), genOway (France), GemPharmatech (China), Cyagen (US), Ozgene Pty Ltd (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Vivo Bio Tech Ltd (India), ingenious targeting laboratory (US), Janvier Labs (France), Champions Oncology, Inc (US), and Vitalstar Biotechnology Co., Ltd. (China) are some of the key companies offering mice model products & services. Research Coverage: This research report categorizes the mice model market by model type & service [model types (inbred mice, genetically engineered mice, hybrid/congenic mice, and outbred mice, breeding services, cryopreservation services, rederivation services, quarantine services, and other services)], by application (drug discovery & development, research applications, and personalized medicine), by technology (CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies), by therapeutic area (oncology, neurology, immunology, metabolic diseases, cardiovascular diseases, and other therapeutic areas), by product end user (pharmaceutical & biotechnology companies, academic & research Institutes, and CROs & CDMOs), by services end user (pharmaceutical & biotechnology companies, government & biomedical research institutes, and CDMOs), and by region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa). The report's scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the mice model market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the mice model market. This report covers the competitive analysis of upcoming startups in the mice model market ecosystem. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the mice model market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities. The report provides insights on the following : • Analysis of key drivers (high adoption of mice models in preclinical studies, the increasing demand for mouse clinical trials, the rising demand for personalized medicine in oncology, technological advancements in genetic engineering), restrains (the introduction of 3D printed models, ethical concerns, and regulatory restrictions), opportunities (Utilization of CRISPR in biomedical research, and the rising demand for disease-specific models), and challenges (development of alternative animal testing methods and genetic & phenotypic variability). • Product approvals: Detailed insights into newly approved products of the mice models market. • Market development: Comprehensive information about lucrative markets – the report analyses the mice model market across varied regions. • Market diversification: Exhaustive information about new products, recent developments, and investments in the mice model market. • Pipeline analysis: Comprehensive information about products under clinical trials. • Competitive assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), JSR Corporation (Japan), and Biocytogen (China).
目錄 Table of Contents
1 INTRODUCTION 40 1.1 STUDY OBJECTIVES 40 1.2 MARKET DEFINITION 40 1.3 MARKET SCOPE 41 1.3.1 INCLUSIONS & EXCLUSIONS 41 1.3.2 MARKETS & REGIONS COVERED 42 1.3.3 YEARS CONSIDERED 43 1.3.4 CURRENCY CONSIDERED 43 1.4 STAKEHOLDERS 43 1.5 SUMMARY OF CHANGES 44 2 RESEARCH METHODOLOGY 45 2.1 RESEARCH DATA 45 2.1.1 SECONDARY DATA 46 2.1.2 PRIMARY DATA 46 2.2 MARKET ESTIMATION METHODOLOGY 47 2.2.1 BOTTOM-UP APPROACH 48 2.2.2 INSIGHTS FROM PRIMARY EXPERTS 50 2.3 TOP-DOWN APPROACH 50 2.4 GROWTH FORECAST 52 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 53 2.6 RESEARCH ASSUMPTIONS 54 2.7 LIMITATIONS 54 2.8 MARKET FORECAST 55 2.9 RISK ANALYSIS 55 3 EXECUTIVE SUMMARY 56 4 PREMIUM INSIGHTS 60 4.1 MICE MODEL MARKET OVERVIEW 60 4.2 NORTH AMERICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE (2024) 61 4.3 MICE MODEL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 61 4.4 MICE MODEL MARKET, BY MODEL TYPE (END USER), 2025 VS. 2030 62 4.5 MICE MODEL MARKET SHARE, BY SERVICES (END USER) 62   5 MARKET OVERVIEW 63 5.1 INTRODUCTION 63 5.2 MARKET DYNAMICS 63 5.2.1 DRIVERS 64 5.2.1.1 High adoption of mice models in preclinical studies 64 5.2.1.2 Increasing demand for Mouse Clinical Trials (MCTs) 65 5.2.1.3 Growing preference for personalized medicine in oncology 66 5.2.1.4 Advancements in genetic engineering 67 5.2.2 RESTRAINTS 67 5.2.2.1 Introduction of 3D printed models 67 5.2.2.2 Ethical concerns and regulatory restrictions 68 5.2.3 OPPORTUNITIES 69 5.2.3.1 Utilization of CRISPR in biomedical research 69 5.2.3.2 Rising demand for disease-specific models 69 5.2.4 CHALLENGES 70 5.2.4.1 Development of alternative animal testing methods 70 5.2.4.2 Genetic & phenotypic variability 71 5.3 MICE MODEL MARKET LANDSCAPE 71 5.3.1 HISTORY OF MICE MODELS 71 5.3.2 MICE MODEL GENERATION PROCESS 72 5.3.3 TECHNIQUES FOR MICE MODEL DEVELOPMENT 72 5.3.4 TECHNOLOGICAL ADVANCEMENTS 73 5.3.5 CONSIDERATIONS FOR MICE MODEL DEVELOPMENT 74 5.4 VALUE CHAIN ANALYSIS 75 5.5 PRICING ANALYSIS 76 5.5.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022−2024 76 5.5.2 AVERAGE SELLING PRICE OF MODEL TYPES, BY REGION, 2024 78 5.6 ECOSYSTEM ANALYSIS 79 5.6.1 MICE MODEL VENDORS 79 5.6.2 MICE MODEL SERVICE VENDORS 80 5.6.3 MICE MODEL END USERS 80 5.6.4 REGULATORY ORGANIZATIONS 81 5.7 TECHNOLOGY ANALYSIS 82 5.7.1 KEY TECHNOLOGIES 82 5.7.1.1 CRISPR/CAS9 gene editing 82 5.7.1.2 Pronuclear Microinjection (PNI) 82 5.7.1.3 Embryo cryopreservation & assisted reproduction 83 5.7.2 COMPLEMENTARY TECHNOLOGIES 83 5.7.2.1 Multimodal preclinical imaging 83 5.7.2.2 Automated behavioural phenotyping 84 5.7.2.3 Integrated physiological monitoring 84 5.7.3 ADJACENT TECHNOLOGIES 84 5.7.3.1 Ex vivo CRISPR screening in cell culture 84 5.7.3.2 High-content bioinformatics pipeline 85 5.7.3.3 Mass spectroscopy-based tissue profiling 85 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 86 5.9 PATENT ANALYSIS 87 5.9.1 METHODOLOGY 87 5.9.2 PATENTS FILED, BY DOCUMENT TYPE, 2014−2024 87 5.10 TRADE DATA ANALYSIS 89 5.10.1 IMPORT DATA 89 5.10.2 IMPORT DATA 90 5.11 KEY CONFERENCES & EVENTS 91 5.11.1 KEY CONFERENCES & EVENTS (2025–2026) 91 5.12 TARIFF & REGULATORY LANDSCAPE 92 5.12.1 TARIFF DATA (HS CODE 106.19.90) 92 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 5.12.3 REGULATORY FRAMEWORK 97 5.12.3.1 North America 97 5.12.3.2 Europe 98 5.12.3.3 China 100 5.12.3.4 Japan 100 5.12.3.5 India 101 5.12.3.6 Australia 102 5.12.3.7 Brazil 102 5.13 PORTER’S FIVE FORCES ANALYSIS 103 5.13.1 THREAT OF NEW ENTRANTS 104 5.13.2 THREAT OF SUBSTITUTES 104 5.13.3 BARGAINING POWER OF BUYERS 104 5.13.4 BARGAINING POWER OF SUPPLIERS 104 5.13.5 INTENSITY OF COMPETITIVE RIVALRY 104 5.14 KEY STAKEHOLDERS & BUYING CRITERIA 105 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 105 5.14.2 ROLE OF STAKEHOLDERS IN BUYING PROCESS 105 5.14.3 BUYING CRITERIA FOR MICE MODEL MARKET 106 5.15 INVESTMENT & FUNDING SCENARIO 107 5.16 IMPACT OF GENERATIVE AI ON MICE MODEL MARKET 108 5.16.1 AI-USE CASES 108 5.16.2 KEY COMPANIES IMPLEMENTING AI 109   5.17 CASE STUDIES 109 5.17.1 CASE STUDY 1: AAV GENE EDITING IN CYAGEN LDLR MUTANT MICE AMELIORATES ATHEROSCLEROSIS 109 5.17.2 CASE STUDY 2: METABOLIC EFFECTS OF SEMAGLUTIDE & TIRZEPATIDE IN DIET-INDUCED OBESE (DIO) MICEBAC 109 5.17.3 CASE STUDY 3: TARGETING NATURAL KILLER CELL ACTIVITY WITH HUMANIZED NSG-IL15 MOUSE MODEL 110 5.18 TRUMP TARIFF IMPACT ON MICE MODEL MARKET 110 5.18.1 KEY TARIFF RATES 110 5.18.2 PRICE IMPACT ANALYSIS 112 5.18.3 KEY IMPACT ON VARIOUS REGIONS 112 5.18.3.1 US 112 5.18.3.2 Europe 112 5.18.3.3 Asia Pacific 113 5.18.3.4 Rest of the World 113 5.18.4 END-USE INDUSTRY IMPACT 113 5.18.4.1 Pharmaceutical & biotechnology companies 113 5.18.4.2 CROs & CDMOs 114 5.18.4.3 Academic & research institutes 114 6 MICE MODEL MARKET, BY MODEL TYPE & SERVICE 115 6.1 INTRODUCTION 116 6.2 MODEL TYPE 116 6.2.1 INBRED MICE 119 6.2.1.1 High utilization across research applications to propel market 119 6.2.2 GENETICALLY ENGINEERED MICE 122 6.2.2.1 Ability to induce mutations for CVD & cancer research to drive market 122 6.2.3 HYBRID/CONGENIC MICE 125 6.2.3.1 Growing focus on biomedical research to boost demand 125 6.2.4 OUTBRED MICE 128 6.2.4.1 Genetic diversity benefits to support market growth 128 6.3 SERVICES 131 6.3.1 BREEDING SERVICES 134 6.3.1.1 Customization of models for specific research applications to boost demand 134 6.3.2 CRYOPRESERVATION SERVICES 137 6.3.2.1 Rising focus on preservation of novel mice models to propel market 137 6.3.3 REDERIVATION SERVICES 140 6.3.3.1 Stringent quality assurance standards to fuel market 140 6.3.4 QUARANTINE SERVICES 143 6.3.4.1 Rising demand for germ-free mice to support market growth 143 6.3.5 OTHER SERVICES 146   7 MICE MODEL MARKET, BY TECHNOLOGY 150 7.1 INTRODUCTION 151 7.2 CRISPR/CAS9 151 7.2.1 ADVANTAGES SUCH AS SIMPLIFIED DESIGN AND COST EFFICIENCY TO PROPEL MARKET 151 7.3 MICROINJECTIONS 155 7.3.1 LOW TOXICITY AND HIGH SUCCESS RATE TO DRIVE MARKET 155 7.4 EMBRYONIC STEM CELL INJECTIONS 158 7.4.1 INCREASING DEMAND FOR TARGETED MICE MODELS IN IMMUNOLOGICAL RESEARCH TO FUEL MARKET 158 7.5 NUCLEAR TRANSFER TECHNIQUE 161 7.5.1 POTENTIAL TO PRODUCE IDENTICAL MICE TO DRIVE MARKET 161 7.6 OTHER TECHNOLOGIES 164 8 MICE MODEL MARKET, BY APPLICATION 167 8.1 INTRODUCTION 168 8.2 DRUG DISCOVERY & DEVELOPMENT 168 8.2.1 INCREASING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET 168 8.3 RESEARCH APPLICATIONS 172 8.3.1 INCREASING FUNDING INVESTMENTS FOR CANCER RESEARCH TO DRIVE MARKET 172 8.4 PERSONALIZED MEDICINE 175 8.4.1 INCREASING PREFERENCE FOR ONCOLOGY THERAPEUTICS TO SUPPORT MARKET GROWTH 175 9 MICE MODEL MARKET, BY THERAPEUTIC AREA 179 9.1 INTRODUCTION 180 9.2 ONCOLOGY 180 9.2.1 GROWING FOCUS ON THERAPEUTIC DEVELOPMENT TO PROPEL MARKET 180 9.3 METABOLIC DISEASES 184 9.3.1 INCREASING PREVALENCE OF ENDOCRINE DISORDERS TO DRIVE MARKET 184 9.4 IMMUNOLOGY 187 9.4.1 RISING CLINICAL RESEARCH ACTIVITIES FOR IMMUNOLOGICAL DISORDERS TO FUEL MARKET 187 9.5 NEUROLOGY 190 9.5.1 INCREASING INVESTMENTS IN R&D FOR CNS DISEASES TO BOOST DEMAND 190 9.6 CARDIOVASCULAR DISEASES 193 9.6.1 GROWING FOCUS ON TARGETED TREATMENTS FOR CVD TO BOOST DEMAND 193 9.7 OTHER THERAPEUTIC AREAS 196   10 MICE MODEL TYPE MARKET, BY END USER 200 10.1 INTRODUCTION 201 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 201 10.2.1 RISING EXPENDITURE ON R&D FOR DRUG DEVELOPMENT TO FUEL MARKET 201 10.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CROS & CDMOS) 205 10.3.1 INCREASING OUTSOURCING OF DRUG DISCOVERY SERVICES TO DRIVE MARKET 205 10.4 ACADEMIC & RESEARCH INSTITUTES 208 10.4.1 INCREASING FUNDING INITIATIVES FOR LIFE SCIENCES R&D TO SUPPORT MARKET GROWTH 208 11 MICE MODEL SERVICES MARKET, BY END USER 211 11.1 INTRODUCTION 212 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 212 11.2.1 RISING OUTSOURCING OF PRECLINICAL SERVICES TO PROPEL MARKET 212 11.3 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS) 215 11.3.1 DEVELOPMENT OF INTEGRATED MODELS AND GROWTH IN BIOLOGICS TO BOOST DEMAND 215 11.4 GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES 218 11.4.1 FOCUS ON TRANSLATIONAL RESEARCH SERVICES TO SUPPORT MARKET GROWTH 218 12 MICE MODEL MARKET, BY REGION 222 12.1 INTRODUCTION 223 12.2 NORTH AMERICA 223 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 223 12.2.2 US 228 12.2.2.1 Rising production of monoclonal antibodies to fuel market 228 12.2.3 CANADA 232 12.2.3.1 Growth in stem cell research activities to fuel market 232 12.3 EUROPE 235 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 235 12.3.2 GERMANY 240 12.3.2.1 Growth in biotechnology industry to drive market 240 12.3.3 UK 243 12.3.3.1 Increasing focus on cancer research to propel market 243 12.3.4 FRANCE 246 12.3.4.1 Rising investments in proteomics & genomics research to boost demand 246 12.3.5 ITALY 249 12.3.5.1 Growth in pharmaceutical & biotechnology industry to drive market 249   12.3.6 SPAIN 252 12.3.6.1 Extensive R&D pipeline to fuel uptake 252 12.3.7 REST OF EUROPE 256 12.4 ASIA PACIFIC 259 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 259 12.4.2 CHINA 265 12.4.2.1 Favorable investments in life sciences research to drive market 265 12.4.3 JAPAN 268 12.4.3.1 Increasing focus on personalized diagnostics products to drive market 268 12.4.4 INDIA 272 12.4.4.1 Favorable initiatives for drug discovery & development to boost market 272 12.4.5 AUSTRALIA 275 12.4.5.1 High number of research institutes to favor market growth 275 12.4.6 SOUTH KOREA 278 12.4.6.1 Innovation in health & biotech sectors to support market uptake 278 12.4.7 REST OF ASIA PACIFIC 281 12.5 LATIN AMERICA 285 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 285 12.5.2 BRAZIL 289 12.5.2.1 Increasing investments in biopharmaceutical research to fuel uptake 289 12.5.3 MEXICO 292 12.5.3.1 Expanding healthcare ecosystem to support market growth 292 12.5.4 REST OF LATIN AMERICA 295 12.6 MIDDLE EAST 299 12.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST 299 12.6.2 GCC COUNTRIES 303 12.6.2.1 Kingdom of Saudi Arabia (KSA) 306 12.6.2.1.1 Growing focus on advancement of healthcare sector to boost market 306 12.6.2.2 United Arab Emirates 310 12.6.2.2.1 Increasing R&D activities and growing demand for personalized medicine to propel market 310 12.6.2.3 Other GCC Countries 314 12.6.3 REST OF MIDDLE EAST 317 12.7 AFRICA 321 12.7.1 RISING PRECISION MEDICINE INITIATIVES TO SUPPORT MARKET GROWTH 321 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 321   13 COMPETITIVE LANDSCAPE 325 13.1 OVERVIEW 325 13.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN 325 13.2.1 STRATEGIES ADOPTED BY KEY PLAYERS IN MICE MODEL MARKET, 2022–2025 326 13.3 REVENUE SHARE ANALYSIS, 2022−2024 328 13.4 MARKET SHARE ANALYSIS 328 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 331 13.5.1 STARS 331 13.5.2 EMERGING LEADERS 331 13.5.3 PERVASIVE PLAYERS 331 13.5.4 PARTICIPANTS 331 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 333 13.5.5.1 Company footprint 333 13.5.5.2 Region footprint 334 13.5.5.3 Model type & service footprint 335 13.5.5.4 Application footprint 336 13.5.5.5 Technology footprint 337 13.5.5.6 Therapeutic area footprint 338 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 339 13.6.1 PROGRESSIVE COMPANIES 339 13.6.2 RESPONSIVE COMPANIES 339 13.6.3 DYNAMIC COMPANIES 339 13.6.4 STARTING BLOCKS 339 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 341 13.6.5.1 Detailed list of key startups/SME players 341 13.6.5.2 Competitive benchmarking of key startups/SMEs 342 13.7 COMPANY VALUATION & FINANCIAL METRICS 343 13.7.1 FINANCIAL METRICS 343 13.7.2 COMPANY VALUATION 343 13.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 344 13.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS FOR MICE MODEL MARKET 344 13.9 COMPETITIVE SCENARIO 345 13.9.1 PRODUCT/SERVICE LAUNCHES 345 13.9.2 DEALS 345 13.9.3 EXPANSIONS 349 13.9.4 OTHER DEVELOPMENTS 351   14 COMPANY PROFILES 352 14.1 KEY PLAYERS 352 14.1.1 CHARLES RIVER LABORATORIES 352 14.1.1.1 Business overview 352 14.1.1.2 Products/Services offered 353 14.1.1.3 Recent developments 356 14.1.1.3.1 Deals 356 14.1.1.3.2 Expansions 357 14.1.1.3.3 Other developments 358 14.1.1.4 MnM view 358 14.1.1.4.1 Key strengths 358 14.1.1.4.2 Strategic choices 358 14.1.1.4.3 Weaknesses & competitive threats 358 14.1.2 THE JACKSON LABORATORY 359 14.1.2.1 Business overview 359 14.1.2.2 Products/Services offered 360 14.1.2.3 Recent developments 366 14.1.2.3.1 Deals 366 14.1.2.3.2 Expansions 367 14.1.2.4 MnM view 368 14.1.2.4.1 Key strengths 368 14.1.2.4.2 Strategic choices 368 14.1.2.4.3 Weaknesses & competitive threats 368 14.1.3 INOTIV 369 14.1.3.1 Business overview 369 14.1.3.2 Products/Services offered 370 14.1.3.3 Recent developments 373 14.1.3.3.1 Deals 373 14.1.3.3.2 Expansions 374 14.1.3.4 MnM view 374 14.1.3.4.1 Key strengths 374 14.1.3.4.2 Strategic choices 374 14.1.3.4.3 Weaknesses & competitive threats 374 14.1.4 JSR CORPORATION 375 14.1.4.1 Business overview 375 14.1.4.2 Product/Services offered 376 14.1.4.3 Recent developments 378 14.1.4.3.1 Deals 378 14.1.4.3.2 Expansions 378 14.1.4.4 MnM view 379 14.1.4.4.1 Key strengths 379 14.1.4.4.2 Strategic choices 379 14.1.4.4.3 Weaknesses & competitive threats 379 14.1.5 BIOCYTOGEN 380 14.1.5.1 Business overview 380 14.1.5.2 Product/Services offered 381 14.1.5.3 Recent developments 383 14.1.5.3.1 Product/Service launches 383 14.1.5.3.2 Deals 383 14.1.5.3.3 Expansions 385 14.1.5.4 MnM view 385 14.1.5.4.1 Key strengths 385 14.1.5.4.2 Strategic choices 385 14.1.5.4.3 Weaknesses & competitive threats 386 14.1.6 SHANGHAI MODEL ORGANISMS CENTER, INC. 387 14.1.6.1 Business overview 387 14.1.6.2 Product/Services offered 388 14.1.6.3 Recent developments 389 14.1.6.3.1 Deals 389 14.1.7 TRANS GENIC INC. 390 14.1.7.1 Business overview 390 14.1.7.2 Products/Services offered 391 14.1.7.3 Recent developments 392 14.1.7.3.1 Deals 392 14.1.8 HARBOUR BIOMED 393 14.1.8.1 Business overview 393 14.1.8.2 Product/Services offered 394 14.1.8.3 Recent developments 395 14.1.8.3.1 Deals 395 14.1.8.3.2 Other developments 397 14.1.9 GENOWAY 398 14.1.9.1 Business overview 398 14.1.9.2 Product/Services offered 399 14.1.9.3 Recent developments 401 14.1.9.3.1 Deals 401 14.1.10 GEMPHARMATECH 402 14.1.10.1 Business overview 402 14.1.10.2 Product/Services offered 403 14.1.10.3 Recent developments 404 14.1.10.3.1 Product/Service launches 404 14.1.10.3.2 Deals 405 14.1.10.3.3 Expansions 405   14.1.11 CYAGEN 406 14.1.11.1 Business overview 406 14.1.11.2 Product/Services offered 406 14.1.11.3 Recent developments 407 14.1.11.3.1 Deals 407 14.1.12 OZGENE PTY LTD. 408 14.1.12.1 Business overview 408 14.1.12.2 Products/Services offered 408 14.1.12.3 Recent developments 409 14.1.12.3.1 Deals 409 14.1.13 TACONIC BIOSCIENCES, INC. 410 14.1.13.1 Business overview 410 14.1.13.2 Products/Services offered 410 14.1.13.3 Recent developments 412 14.1.13.3.1 Product/Service launches 412 14.1.13.3.2 Deals 413 14.1.13.3.3 Expansions 413 14.1.14 TRANSCURE BIOSERVICES 414 14.1.14.1 Business overview 414 14.1.14.2 Products/Services offered 414 14.1.14.3 Recent developments 415 14.1.14.3.1 Deals 415 14.1.15 VIVO BIO TECH LTD. 416 14.1.15.1 Business overview 416 14.1.15.2 Product/Services offered 417 14.1.16 INGENIOUS TARGETING LABORATORY 418 14.1.16.1 Business overview 418 14.1.16.2 Product/Services offered 418 14.1.17 JANVIER LABS 420 14.1.17.1 Business overview 420 14.1.17.2 Product/Services offered 420 14.1.17.3 Recent developments 423 14.1.17.3.1 Deals 423 14.1.18 CHAMPIONS ONCOLOGY, INC. 424 14.1.18.1 Business overview 424 14.1.18.2 Products offered 425 14.1.18.3 Recent developments 425 14.1.18.3.1 Deals 425 14.1.19 VITALSTAR BIOTECHNOLOGY CO., LTD. 426 14.1.19.1 Business overview 426 14.1.19.2 Products offered 426   14.2 OTHER PLAYERS 427 14.2.1 ONCODESIGN SERVICES 427 14.2.2 CLEA JAPAN, INC. 428 14.2.3 APPLIED STEMCELL 429 14.2.4 CREATIVE ANIMODEL 430 14.2.5 JOINN LABORATORIES (CHINA) CO., LTD. 431 14.2.6 CREATIVE BIOLABS 432 14.2.7 CRESCENDO BIOLOGICS LIMITED 433 14.2.8 ARAGEN LIFE SCIENCES LTD. 434 14.2.9 POLYGENE 435 14.2.10 PHARMTEST SERVICES 436 14.2.11 MARSHALL BIORESOURCES 437 15 APPENDIX 438 15.1 DISCUSSION GUIDE 438 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 442 15.3 CUSTOMIZATION OPTIONS 444 15.4 RELATED REPORTS 444 15.5 AUTHOR DETAILS 445
圖表清單 List of Tables & Figures
TABLE 1 MICE MODEL MARKET: IMPACT ANALYSIS 55 TABLE 2 MICE MODEL MARKET: RISK ASSESSMENT ANALYSIS 55 TABLE 3 MICE MODEL MARKET: IMPACT ANALYSIS 64 TABLE 4 AVERAGE SELLING PRICE TREND OF MODEL TYPES, BY KEY PLAYER, 20222−2024 76 TABLE 5 AVERAGE SELLING PRICE OF MODEL TYPES, BY REGION, 2024 78 TABLE 6 MICE MODEL MARKET: ROLE IN ECOSYSTEM, BY VENDORS 80 TABLE 7 MICE MODEL MARKET: ROLE IN ECOSYSTEM, BY SERVICE VENDOR 80 TABLE 8 MICE MODEL MARKET: ROLE IN ECOSYSTEM, BY END USER 81 TABLE 9 MICE MODEL MARKET: ROLE IN ECOSYSTEM, BY REGULATORY ORGANIZATION 81 TABLE 10 PATENTS FILED, BY DOCUMENT TYPE, 2014−2024 87 TABLE 11 PATENTS IN MICE MODELS MARKET 89 TABLE 12 IMPORT VALUE OF HS CODE 106.19.90–COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020−2024 (USD THOUSANDS) 89 TABLE 13 IMPORT VALUE OF HS CODE 106.19.90−COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020−2024 (USD THOUSANDS) 90 TABLE 14 MICE MODEL MARKET: CONFERENCES & EVENTS (2025–2026) 91 TABLE 15 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 16 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 17 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94 TABLE 18 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95 TABLE 19 MICE MODEL MARKET: REGULATORY SCENARIO 95 TABLE 20 MICE MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS 103 TABLE 21 INVESTMENT & FUNDING ACTIVITIES, BY KEY PLAYER, 2022−2025 107 TABLE 22 US-ADJUSTED RECIPROCAL TARIFF RATES 110 TABLE 23 KEY PRODUCT-RELATED TARIFFS: LIVE ANIMALS, PRODUCT OF ANIMAL ORIGIN, AND MISCELLANEOUS CHEMICAL PRODUCTS 111 TABLE 24 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES 112 TABLE 25 MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 116 TABLE 26 MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 27 NORTH AMERICA: MICE MODEL TYPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 28 EUROPE: MICE MODEL TYPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 29 ASIA PACIFIC: MICE MODEL TYPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 30 LATIN AMERICA: MICE MODEL TYPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 31 MIDDLE EAST: MICE MODEL TYPE MARKET, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 32 GCC COUNTRIES: MICE MODEL TYPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 33 MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 119 TABLE 34 INBRED MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 35 NORTH AMERICA: INBRED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 36 EUROPE: INBRED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 37 ASIA PACIFIC: INBRED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 38 LATIN AMERICA: INBRED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 39 MIDDLE EAST: INBRED MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 40 GCC COUNTRIES: INBRED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 41 GENETICALLY ENGINEERED MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 42 NORTH AMERICA: GENETICALLY ENGINEERED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 43 EUROPE: GENETICALLY ENGINEERED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 44 ASIA PACIFIC: GENETICALLY ENGINEERED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 45 LATIN AMERICA: GENETICALLY ENGINEERED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 46 MIDDLE EAST: GENETICALLY ENGINEERED MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 47 GCC COUNTRIES: GENETICALLY ENGINEERED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 48 HYBRID/CONGENIC MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 49 NORTH AMERICA: HYBRID/CONGENIC MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 50 EUROPE: HYBRID/CONGENIC MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 51 ASIA PACIFIC: HYBRID/CONGENIC MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 52 LATIN AMERICA: HYBRID/CONGENIC MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 53 MIDDLE EAST: HYBRID/CONGENIC MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 54 GCC COUNTRIES: HYBRID/CONGENIC MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 55 OUTBRED MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 128 TABLE 56 NORTH AMERICA: OUTBRED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 57 EUROPE: OUTBRED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 58 ASIA PACIFIC: OUTBRED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 59 LATIN AMERICA: OUTBRED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 60 MIDDLE EAST: OUTBRED MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 61 GCC COUNTRIES: OUTBRED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 62 MICE MODEL SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 63 NORTH AMERICA: MICE MODEL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 64 EUROPE: MICE MODEL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 65 ASIA PACIFIC: MICE MODEL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 66 LATIN AMERICA: MICE MODEL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 67 MIDDLE EAST: MICE MODEL SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 133 TABLE 68 GCC COUNTRIES: MICE MODEL SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 69 MICE MODEL SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 133 TABLE 70 MICE MODEL BREEDING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 71 NORTH AMERICA: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 72 EUROPE: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 73 ASIA PACIFIC: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 74 LATIN AMERICA: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 75 MIDDLE EAST: MICE MODEL BREEDING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 76 GCC COUNTRIES: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 77 MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 78 NORTH AMERICA: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 79 EUROPE: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 80 ASIA PACIFIC: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 81 LATIN AMERICA: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 82 MIDDLE EAST: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY REGION 2023–2030 (USD MILLION) 139 TABLE 83 GCC COUNTRIES: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 84 MICE MODEL REDERIVATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 141 TABLE 85 NORTH AMERICA: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 86 EUROPE: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 87 ASIA PACIFIC: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 88 LATIN AMERICA: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 89 MIDDLE EAST: MICE MODEL REDERIVATION SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 90 GCC COUNTRIES: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 91 MICE MODEL QUARANTINE SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 92 NORTH AMERICA: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 93 EUROPE: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 94 ASIA PACIFIC: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 95 LATIN AMERICA: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 96 MIDDLE EAST: MICE MODEL QUARANTINE SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 145 TABLE 97 GCC COUNTRIES: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 98 MICE MODEL MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 99 NORTH AMERICA: MICE MODEL MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 100 EUROPE: MICE MODEL MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 101 ASIA PACIFIC: MICE MODEL MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 102 LATIN AMERICA: MICE MODEL MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 103 MIDDLE EAST: MICE MODEL MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD MILLION) 148 TABLE 104 GCC COUNTRIES: MICE MODEL MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 105 MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 151 TABLE 106 MICE MODEL MARKET FOR CRISPR/CAS9, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 107 NORTH AMERICA: MICE MODEL MARKET FOR CRISPR/CAS9, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 108 EUROPE: MICE MODEL MARKET FOR CRISPR/CAS9, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 109 ASIA PACIFIC: MICE MODEL MARKET FOR CRISPR/CAS9, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 110 LATIN AMERICA: MICE MODEL MARKET FOR CRISPR/CAS9, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 111 MIDDLE EAST: MICE MODEL MARKET FOR CRISPR/CAS9, BY REGION, 2023–2030 (USD MILLION) 154 TABLE 112 GCC COUNTRIES: MICE MODEL MARKET FOR CRISPR/CAS9, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 113 MICE MODEL MARKET FOR MICROINJECTIONS, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 114 NORTH AMERICA: MICE MODEL MARKET FOR MICROINJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 115 EUROPE: MICE MODEL MARKET FOR MICROINJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 116 ASIA PACIFIC: MICE MODEL MARKET FOR MICROINJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 117 LATIN AMERICA: MICE MODEL MARKET FOR MICROINJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 118 MIDDLE EAST: MICE MODEL MARKET FOR MICROINJECTIONS, BY REGION, 2023–2030 (USD MILLION) 157 TABLE 119 GCC COUNTRIES: MICE MODEL MARKET FOR MICROINJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 120 MICE MODEL MARKET FOR EMBRYONIC STEM CELL INJECTIONS, BY REGION, 2023–2030 (USD MILLION) 158 TABLE 121 NORTH AMERICA: MICE MODEL MARKET FOR EMBRYONIC STEM CELL INJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 122 EUROPE: MICE MODEL MARKET FOR EMBRYONIC STEM CELL INJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 123 ASIA PACIFIC: MICE MODEL MARKET FOR EMBRYONIC STEM CELL INJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 124 LATIN AMERICA: MICE MODELS MARKET FOR EMBRYONIC STEM CELL INJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 125 MIDDLE EAST: MICE MODELS MARKET FOR EMBRYONIC STEM CELL INJECTIONS, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 126 GCC COUNTRIES: MICE MODELS MARKET FOR EMBRYONIC STEM CELL INJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 127 MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE, BY REGION, 2023–2030 (USD MILLION) 161 TABLE 128 NORTH AMERICA: MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 129 EUROPE: MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 130 ASIA PACIFIC: MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 131 LATIN AMERICA: MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 132 MIDDLE EAST: MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE, BY REGION, 2023–2030 (USD MILLION) 163 TABLE 133 GCC COUNTRIES: MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 134 MICE MODEL MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 135 NORTH AMERICA: MICE MODEL MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 136 EUROPE: MICE MODEL MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 137 ASIA PACIFIC: MICE MODEL MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 138 LATIN AMERICA: MICE MODEL MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 139 MIDDLE EAST: MICE MODEL MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 140 GCC COUNTRIES: MICE MODEL MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 141 MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 168 TABLE 142 MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 143 NORTH AMERICA: MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 144 EUROPE: MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 145 ASIA PACIFIC: MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 146 LATIN AMERICA: MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 147 MIDDLE EAST: MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 148 GCC COUNTRIES: MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 149 MICE MODEL MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 150 NORTH AMERICA: MICE MODEL MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 151 EUROPE: MICE MODEL MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 152 ASIA PACIFIC: MICE MODEL MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 153 LATIN AMERICA: MICE MODEL MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 154 MIDDLE EAST: MICE MODEL MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 174 TABLE 155 GCC COUNTRIES: MICE MODEL MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 156 MICE MODEL MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 157 NORTH AMERICA: MICE MODEL MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 158 EUROPE: MICE MODEL MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 159 ASIA PACIFIC: MICE MODEL MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 160 LATIN AMERICA: MICE MODEL MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 161 MIDDLE EAST: MICE MODEL MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023–2030 (USD MILLION) 177 TABLE 162 GCC COUNTRIES: MICE MODEL MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 163 MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 180 TABLE 164 MICE MODEL MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 165 NORTH AMERICA: MICE MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 166 EUROPE: MICE MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 167 ASIA PACIFIC: MICE MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 168 LATIN AMERICA: MICE MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 169 MIDDLE EAST: MICE MODEL MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 183 TABLE 170 GCC COUNTRIES: MICE MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 171 MICE MODEL MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION) 184 TABLE 172 NORTH AMERICA: MICE MODEL MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 173 EUROPE: MICE MODEL MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 174 ASIA PACIFIC: MICE MODEL MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 175 LATIN AMERICA: MICE MODEL MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 176 MIDDLE EAST: MICE MODEL MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION) 186 TABLE 177 GCC COUNTRIES: MICE MODEL MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 178 MICE MODEL MARKET FOR IMMUNOLOGY, BY REGION, 2023–2030 (USD MILLION) 187 TABLE 179 NORTH AMERICA: MICE MODEL MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 180 EUROPE: MICE MODEL MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 181 ASIA PACIFIC: MICE MODEL MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 182 LATIN AMERICA: MICE MODEL MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 183 MIDDLE EAST: MICE MODEL MARKET FOR IMMUNOLOGY, BY REGION, 2023–2030 (USD MILLION) 189 TABLE 184 GCC COUNTRIES: MICE MODEL MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 185 MICE MODEL MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION) 190 TABLE 186 NORTH AMERICA: MICE MODEL MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 187 EUROPE: MICE MODEL MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 188 ASIA PACIFIC: MICE MODEL MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 189 LATIN AMERICA: MICE MODEL MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 190 MIDDLE EAST: MICE MODEL MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION) 192 TABLE 191 GCC COUNTRIES: MICE MODEL MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 192 MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 193 TABLE 193 NORTH AMERICA: MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 194 EUROPE: MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 195 ASIA PACIFIC: MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 196 LATIN AMERICA: MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 197 MIDDLE EAST: MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 195 TABLE 198 GCC COUNTRIES: MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 199 MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 197 TABLE 200 NORTH AMERICA: MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 201 EUROPE: MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 202 ASIA PACIFIC: MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 203 LATIN AMERICA: MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 204 MIDDLE EAST: MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 198 TABLE 205 GCC COUNTRIES: MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 206 MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 201 TABLE 207 MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 202 TABLE 208 NORTH AMERICA: MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 209 EUROPE: MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 210 ASIA PACIFIC: MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 211 LATIN AMERICA: MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 212 MIDDLE EAST: MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 204 TABLE 213 GCC COUNTRIES: MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 214 MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY REGION, 2023–2030 (USD MILLION) 205 TABLE 215 NORTH AMERICA: MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 216 EUROPE: MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 217 ASIA PACIFIC: MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 218 LATIN AMERICA: MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 USD MILLION) 207 TABLE 219 MIDDLE EAST: MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY REGION, 2023–2030 (USD MILLION) 207 TABLE 220 GCC COUNTRIES: MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 221 MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 208 TABLE 222 NORTH AMERICA: MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 223 EUROPE: MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 224 ASIA PACIFIC: MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 225 LATIN AMERICA: MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 226 MIDDLE EAST: MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 210 TABLE 227 GCC COUNTRIES: MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 228 MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 212 TABLE 229 MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 213 TABLE 230 NORTH AMERICA: MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 231 EUROPE: MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 232 ASIA PACIFIC: MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 233 LATIN AMERICA: MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 234 MIDDLE EAST: MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 214 TABLE 235 GCC COUNTRIES: MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 236 MICE MODEL SERVICES MARKET FOR CDMOS, BY REGION, 2023–2030 (USD MILLION) 216 TABLE 237 NORTH AMERICA: MICE MODEL SERVICES MARKET FOR CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 238 EUROPE: MICE MODEL SERVICES MARKET FOR CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 239 ASIA PACIFIC: MICE MODEL SERVICES MARKET FOR CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 240 LATIN AMERICA: MICE MODEL SERVICES MARKET FOR CDMOS, BY COUNTRY, 2023–2030 USD MILLION) 217 TABLE 241 MIDDLE EAST: MICE MODEL SERVICES MARKET FOR CDMOS, BY REGION, 2023–2030 (USD MILLION) 217 TABLE 242 GCC COUNTRIES: MICE MODEL SERVICES MARKET FOR CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 243 MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 219 TABLE 244 NORTH AMERICA: MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 245 EUROPE: MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 246 ASIA PACIFIC: MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 247 LATIN AMERICA: MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 248 MIDDLE EAST: MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 220 TABLE 249 GCC COUNTRIES: MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 221 TABLE 250 MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 223 TABLE 251 NORTH AMERICA: MACROECONOMIC INDICATORS 224 TABLE 252 NORTH AMERICA: MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 225 TABLE 253 NORTH AMERICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 226 TABLE 254 NORTH AMERICA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 226 TABLE 255 NORTH AMERICA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 226 TABLE 256 NORTH AMERICA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 227 TABLE 257 NORTH AMERICA: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 227 TABLE 258 NORTH AMERICA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 227 TABLE 259 NORTH AMERICA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 228 TABLE 260 NORTH AMERICA: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 228 TABLE 261 US: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 229 TABLE 262 US: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 230 TABLE 263 US: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 230 TABLE 264 US: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 230 TABLE 265 US: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 231 TABLE 266 US: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 231 TABLE 267 US: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 231 TABLE 268 US: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 232 TABLE 269 CANADA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 233 TABLE 270 CANADA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 233 TABLE 271 CANADA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 233 TABLE 272 CANADA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 234 TABLE 273 CANADA: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 234 TABLE 274 CANADA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 234 TABLE 275 CANADA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 235 TABLE 276 CANADA: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 235 TABLE 277 EUROPE: MACROECONOMIC INDICATORS 236 TABLE 278 EUROPE: MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 237 TABLE 279 EUROPE: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 237 TABLE 280 EUROPE: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 281 EUROPE: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 238 TABLE 282 EUROPE: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 238 TABLE 283 EUROPE: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 238 TABLE 284 EUROPE: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 239 TABLE 285 EUROPE: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 239 TABLE 286 EUROPE: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 239 TABLE 287 GERMANY: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 240 TABLE 288 GERMANY: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 289 GERMANY: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 241 TABLE 290 GERMANY: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 241 TABLE 291 GERMANY: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 242 TABLE 292 GERMANY: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 242 TABLE 293 GERMANY: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 242 TABLE 294 GERMANY: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 243 TABLE 295 UK: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 243 TABLE 296 UK: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 244 TABLE 297 UK: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 244 TABLE 298 UK: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 244 TABLE 299 UK: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 245 TABLE 300 UK: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 245 TABLE 301 UK: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 245 TABLE 302 UK: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 246 TABLE 303 FRANCE: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 246 TABLE 304 FRANCE: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 305 FRANCE: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 247 TABLE 306 FRANCE: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 247 TABLE 307 FRANCE: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 248 TABLE 308 FRANCE: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 248 TABLE 309 FRANCE: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 248 TABLE 310 FRANCE: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 249 TABLE 311 ITALY: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 250 TABLE 312 ITALY: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 250 TABLE 313 ITALY: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 250 TABLE 314 ITALY: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 251 TABLE 315 ITALY: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 251 TABLE 316 ITALY: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 251 TABLE 317 ITALY: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 252 TABLE 318 ITALY: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 252 TABLE 319 SPAIN: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 253 TABLE 320 SPAIN: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 321 SPAIN: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 254 TABLE 322 SPAIN: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 254 TABLE 323 SPAIN: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 254 TABLE 324 SPAIN: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 255 TABLE 325 SPAIN: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 255 TABLE 326 SPAIN: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 255 TABLE 327 REST OF EUROPE: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 256 TABLE 328 REST OF EUROPE: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 329 REST OF EUROPE: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 257 TABLE 330 REST OF EUROPE: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 257 TABLE 331 REST OF EUROPE: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 258 TABLE 332 REST OF EUROPE: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 258 TABLE 333 REST OF EUROPE: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 258 TABLE 334 REST OF EUROPE: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 259 TABLE 335 ASIA PACIFIC: MACROECONOMIC INDICATORS 260 TABLE 336 ASIA PACIFIC: MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 262 TABLE 337 ASIA PACIFIC: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 262 TABLE 338 ASIA PACIFIC: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 262 TABLE 339 ASIA PACIFIC: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 263 TABLE 340 ASIA PACIFIC: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 263 TABLE 341 ASIA PACIFIC: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 264 TABLE 342 ASIA PACIFIC: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 264 TABLE 343 ASIA PACIFIC: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 264 TABLE 344 ASIA PACIFIC: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 265 TABLE 345 CHINA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 266 TABLE 346 CHINA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 266 TABLE 347 CHINA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 266 TABLE 348 CHINA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 267 TABLE 349 CHINA: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 267 TABLE 350 CHINA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 267 TABLE 351 CHINA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 268 TABLE 352 CHINA: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 268 TABLE 353 JAPAN: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 269 TABLE 354 JAPAN: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 269 TABLE 355 JAPAN: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 270 TABLE 356 JAPAN: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 270 TABLE 357 JAPAN: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 270 TABLE 358 JAPAN: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 271 TABLE 359 JAPAN: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 271 TABLE 360 JAPAN: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 271 TABLE 361 INDIA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 272 TABLE 362 INDIA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 273 TABLE 363 INDIA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 273 TABLE 364 INDIA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 273 TABLE 365 INDIA: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 274 TABLE 366 INDIA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 274 TABLE 367 INDIA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 274 TABLE 368 INDIA: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 275 TABLE 369 AUSTRALIA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 276 TABLE 370 AUSTRALIA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 276 TABLE 371 AUSTRALIA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 276 TABLE 372 AUSTRALIA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 277 TABLE 373 AUSTRALIA: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 277 TABLE 374 AUSTRALIA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 277 TABLE 375 AUSTRALIA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 278 TABLE 376 AUSTRALIA: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 278 TABLE 377 SOUTH KOREA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 279 TABLE 378 SOUTH KOREA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 379 SOUTH KOREA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 279 TABLE 380 SOUTH KOREA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 280 TABLE 381 SOUTH KOREA: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 280 TABLE 382 SOUTH KOREA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 280 TABLE 383 SOUTH KOREA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 281 TABLE 384 SOUTH KOREA: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 281 TABLE 385 REST OF ASIA PACIFIC: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 282 TABLE 386 REST OF ASIA PACIFIC: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 387 REST OF ASIA PACIFIC: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 283 TABLE 388 REST OF ASIA PACIFIC: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 283 TABLE 389 REST OF ASIA PACIFIC: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 284 TABLE 390 REST OF ASIA PACIFIC: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 284 TABLE 391 REST OF ASIA PACIFIC: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 284 TABLE 392 REST OF ASIA PACIFIC: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 285 TABLE 393 LATIN AMERICA: MACROECONOMIC INDICATORS 286 TABLE 394 LATIN AMERICA: MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 286 TABLE 395 LATIN AMERICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 286 TABLE 396 LATIN AMERICA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 287 TABLE 397 LATIN AMERICA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 287 TABLE 398 LATIN AMERICA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 287 TABLE 399 LATIN AMERICA: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 288 TABLE 400 LATIN AMERICA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 288 TABLE 401 LATIN AMERICA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 288 TABLE 402 LATIN AMERICA: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 289 TABLE 403 BRAZIL: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 290 TABLE 404 BRAZIL: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 290 TABLE 405 BRAZIL: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 290 TABLE 406 BRAZIL: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 291 TABLE 407 BRAZIL: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 291 TABLE 408 BRAZIL: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 291 TABLE 409 BRAZIL: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 292 TABLE 410 BRAZIL: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 292 TABLE 411 MEXICO: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 293 TABLE 412 MEXICO: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 293 TABLE 413 MEXICO: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 293 TABLE 414 MEXICO: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 294 TABLE 415 MEXICO: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 294 TABLE 416 MEXICO: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 294 TABLE 417 MEXICO: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 295 TABLE 418 MEXICO: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 295 TABLE 419 REST OF LATIN AMERICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 296 TABLE 420 REST OF LATIN AMERICA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 296 TABLE 421 REST OF LATIN AMERICA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 297 TABLE 422 REST OF LATIN AMERICA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 297 TABLE 423 REST OF LATIN AMERICA: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 298 TABLE 424 REST OF LATIN AMERICA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 298 TABLE 425 REST OF LATIN AMERICA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 298 TABLE 426 REST OF LATIN AMERICA: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 299 TABLE 427 MIDDLE EAST: MACROECONOMIC INDICATORS 300 TABLE 428 MIDDLE EAST: MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 300 TABLE 429 MIDDLE EAST: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 300 TABLE 430 MIDDLE EAST: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 301 TABLE 431 MIDDLE EAST: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 301 TABLE 432 MIDDLE EAST: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 301 TABLE 433 MIDDLE EAST: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 302 TABLE 434 MIDDLE EAST: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 302 TABLE 435 MIDDLE EAST: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 302 TABLE 436 MIDDLE EAST: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 303 TABLE 437 GCC COUNTRIES: MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 303 TABLE 438 GCC COUNTRIES: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 304 TABLE 439 GCC COUNTRIES: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 440 GCC COUNTRIES: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 304 TABLE 441 GCC COUNTRIES: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 305 TABLE 442 GCC COUNTRIES: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 305 TABLE 443 GCC COUNTRIES: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 305 TABLE 444 GCC COUNTRIES: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 306 TABLE 445 GCC COUNTRIES: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 306 TABLE 446 KINGDOM OF SAUDI ARABIA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 307 TABLE 447 KINGDOM OF SAUDI ARABIA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 307 TABLE 448 KINGDOM OF SAUDI ARABIA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 308 TABLE 449 KINGDOM OF SAUDI ARABIA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 308 TABLE 450 KINGDOM OF SAUDI ARABIA: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 309 TABLE 451 KINGDOM OF SAUDI ARABIA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 309 TABLE 452 KINGDOM OF SAUDI ARABIA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 309 TABLE 453 KINGDOM OF SAUDI ARABIA: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 310 TABLE 454 UNITED ARAB EMIRATES: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 311 TABLE 455 UNITED ARAB EMIRATES: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 311 TABLE 456 UNITED ARAB EMIRATES: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 311 TABLE 457 UNITED ARAB EMIRATES: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 312 TABLE 458 UNITED ARAB EMIRATES: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 312 TABLE 459 UNITED ARAB EMIRATES: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 313 TABLE 460 UNITED ARAB EMIRATES: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 313   TABLE 461 UNITED ARAB EMIRATES: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 313 TABLE 462 OTHER GCC COUNTRIES: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 314 TABLE 463 OTHER GCC COUNTRIES: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 315 TABLE 464 OTHER GCC COUNTRIES: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 315 TABLE 465 OTHER GCC COUNTRIES: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 315 TABLE 466 OTHER GCC COUNTRIES: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 316 TABLE 467 OTHER GCC COUNTRIES: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 316 TABLE 468 OTHER GCC COUNTRIES: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 316 TABLE 469 OTHER GCC COUNTRIES: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 317 TABLE 470 REST OF MIDDLE EAST: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 318 TABLE 471 REST OF MIDDLE EAST: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 318 TABLE 472 REST OF MIDDLE EAST: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 318 TABLE 473 REST OF MIDDLE EAST: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 319 TABLE 474 REST OF MIDDLE EAST: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 319 TABLE 475 REST OF MIDDLE EAST: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 320 TABLE 476 REST OF MIDDLE EAST: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 320 TABLE 477 REST OF MIDDLE EAST: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 320 TABLE 478 MACROECONOMIC OUTLOOK FOR AFRICA 322 TABLE 479 AFRICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 322 TABLE 480 AFRICA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 322 TABLE 481 AFRICA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION) 323 TABLE 482 AFRICA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 323 TABLE 483 AFRICA: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 323 TABLE 484 AFRICA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 324 TABLE 485 AFRICA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION) 324 TABLE 486 AFRICA: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 324 TABLE 487 STRATEGIES ADOPTED BY KEY PLAYERS IN MICE MODEL MARKET, 2022−2025 326 TABLE 488 MICE MODEL MARKET: INTENSITY OF COMPETITIVE RIVALRY 329   TABLE 489 MICE MODEL MARKET: REGION FOOTPRINT 334 TABLE 490 MICE MODEL MARKET: MODEL TYPE & SERVICE FOOTPRINT 335 TABLE 491 MICE MODEL MARKET: APPLICATION FOOTPRINT 336 TABLE 492 MICE MODEL MARKET: TECHNOLOGY FOOTPRINT 337 TABLE 493 MICE MODEL MARKET: THERAPEUTIC AREA FOOTPRINT 338 TABLE 494 MICE MODEL MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 341 TABLE 495 MICE MODEL MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 342 TABLE 496 MICE MODEL MARKET: PRODUCT/SERVICE LAUNCHES, JANUARY 2022−JUNE 2025 345 TABLE 497 MICE MODEL MARKET: DEALS, JANUARY 2022−JUNE 2025 345 TABLE 498 MICE MODEL MARKET: EXPANSIONS, JANUARY 2022−JUNE 2025 349 TABLE 499 MICE MODEL MARKET: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025 351 TABLE 500 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 352 TABLE 501 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED 353 TABLE 502 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022−JUNE 2025 356 TABLE 503 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022−JUNE 2025 357 TABLE 504 CHARLES RIVER LABORATORIES: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025 358 TABLE 505 THE JACKSON LABORATORY: COMPANY OVERVIEW 359 TABLE 506 THE JACKSON LABORATORY: PRODUCTS/SERVICES OFFERED 360 TABLE 507 THE JACKSON LABORATORY: DEALS, JANUARY 2022−JUNE 2025 366 TABLE 508 THE JACKSON LABORATORY: EXPANSIONS, JANUARY 2022−JUNE 2025 367 TABLE 509 INOTIV: COMPANY OVERVIEW 369 TABLE 510 INOTIV: PRODUCTS/SERVICES OFFERED 370 TABLE 511 INOTIV: DEALS, JANUARY 2022−JUNE 2025 373 TABLE 512 INOTIV: EXPANSIONS, JANUARY 2022−JUNE 2025 374 TABLE 513 JSR CORPORATION: COMPANY OVERVIEW 375 TABLE 514 JSR CORPORATION: PRODUCTS/SERVICES OFFERED 376 TABLE 515 JSR CORPORATION: DEALS, JANUARY 2022−JUNE 2025 378 TABLE 516 JSR CORPORATION: EXPANSIONS, JANUARY 2022−JUNE 2025 378 TABLE 517 BIOCYTOGEN: COMPANY OVERVIEW 380 TABLE 518 BIOCYTOGEN: PRODUCTS/SERVICES OFFERED 381 TABLE 519 BIOCYTOGEN: PRODUCT/SERVICE LAUNCHES, JANUARY 2022−JUNE 2025 383 TABLE 520 BIOCYTOGEN: DEALS, JANUARY 2022−JUNE 2025 383 TABLE 521 BIOCYTOGEN: EXPANSIONS, JANUARY 2022−JUNE 2025 385 TABLE 522 SHANGHAI MODEL ORGANISMS CENTER, INC.: COMPANY OVERVIEW 387 TABLE 523 SHANGHAI MODEL ORGANISMS CENTER, INC.: PRODUCTS/SERVICES OFFERED 388 TABLE 524 SHANGHAI MODEL ORGANISMS CENTER, INC.: DEALS, JANUARY 2022−JUNE 2025 389 TABLE 525 TRANS GENIC INC.: COMPANY OVERVIEW 390 TABLE 526 TRANS GENIC, INC.: PRODUCTS/SERVICES OFFERED 391 TABLE 527 TRANS GENIC, INC.: DEALS, JANUARY 2022−JUNE 2025 392   TABLE 528 HARBOUR BIOMED: COMPANY OVERVIEW 393 TABLE 529 HARBOUR BIOMED: PRODUCTS/SERVICES OFFERED 394 TABLE 530 HARBOUR BIOMED: DEALS, JANUARY 2022−JUNE 2025 395 TABLE 531 HARBOUR BIOMED: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025 397 TABLE 532 GENOWAY: COMPANY OVERVIEW 398 TABLE 533 GENOWAY: PRODUCTS/SERVICES OFFERED 399 TABLE 534 GENOWAY: DEALS, JANUARY 2022−JUNE 2025 401 TABLE 535 GEMPHARMATECH: COMPANY OVERVIEW 402 TABLE 536 GEMPHARMATECH: PRODUCTS/SERVICES OFFERED 403 TABLE 537 GEMPHARMATECH: PRODUCT/SERVICE LAUNCHES, JANUARY 2022−JUNE 2025 404 TABLE 538 GEMPHARMATECH: DEALS, JANUARY 2022−JUNE 2025 405 TABLE 539 GEMPHARMATECH: EXPANSIONS, JANUARY 2022−JUNE 2025 405 TABLE 540 CYAGEN: COMPANY OVERVIEW 406 TABLE 541 CYAGEN: PRODUCTS/SERVICES OFFERED 406 TABLE 542 CYAGEN: DEALS, JANUARY 2022−JUNE 2025 407 TABLE 543 OZGENE PTY LTD.: COMPANY OVERVIEW 408 TABLE 544 OZGENE PTY LTD.: PRODUCTS/SERVICES OFFERED 408 TABLE 545 OZGENE PTY. LTD: DEALS, JANUARY 2022−JUNE 2025 409 TABLE 546 TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW 410 TABLE 547 TACONIC BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED 410 TABLE 548 TACONIC BIOSCIENCES, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2022−JUNE 2025 412 TABLE 549 TACONIC BIOSCIENCES, INC.: DEALS, JANUARY 2022−JUNE 2025 413 TABLE 550 TACONIC BIOSCIENCES, INC.: EXPANSIONS, JANUARY 2022−JUNE 2025 413 TABLE 551 TRANSCURE BIOSERVICES: COMPANY OVERVIEW 414 TABLE 552 TRANSCURE BIOSERVICES: PRODUCTS/SERVICES OFFERED 414 TABLE 553 TRANSCURE BIOSERVICES: DEALS, JANUARY 2022−JUNE 2025 415 TABLE 554 VIVO BIO TECH LTD.: COMPANY OVERVIEW 416 TABLE 555 VIVO BIO TECH LTD.: PRODUCTS/SERVICES OFFERED 417 TABLE 556 INGENIOUS TARGETING LABORATORY: COMPANY OVERVIEW 418 TABLE 557 INGENIOUS TARGETING LABORATORY: PRODUCTS/SERVICES OFFERED 418 TABLE 558 JANVIER LABS: COMPANY OVERVIEW 420 TABLE 559 JANVIER LABS: PRODUCTS/SERVICES OFFERED 420 TABLE 560 JANVIER LABS: DEALS, JANUARY 2022−JUNE 2025 423 TABLE 561 CHAMPIONS ONCOLOGY, INC.: COMPANY OVERVIEW 424 TABLE 562 CHAMPIONS ONCOLOGY, INC.: PRODUCTS OFFERED 425 TABLE 563 CHAMPIONS ONCOLOGY, INC.: DEALS, JANUARY 2022−JUNE 2025 425 TABLE 564 VITALSTAR BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 426 TABLE 565 VITALSTAR BIOTECHNOLOGY CO., LTD.: PRODUCTS OFFERED 426 TABLE 566 ONCODESIGN SERVICES: COMPANY OVERVIEW 427 TABLE 567 CLEA JAPAN, INC.: COMPANY OVERVIEW 428   TABLE 568 APPLIED STEMCELL: COMPANY OVERVIEW 429 TABLE 569 CREATIVE ANIMODEL: COMPANY OVERVIEW 430 TABLE 570 JOINN LABORATORIES (CHINA) CO., LTD.: COMPANY OVERVIEW 431 TABLE 571 CREATIVE BIOLABS: COMPANY OVERVIEW 432 TABLE 572 CRESCENDO BIOLOGICS LIMITED: COMPANY OVERVIEW 433 TABLE 573 ARAGEN LIFE SCIENCES LTD.: BUSINESS OVERVIEW 434 TABLE 574 POLYGENE: BUSINESS OVERVIEW 435 TABLE 575 PHARMATEST: BUSINESS OVERVIEW 436 TABLE 576 MARSHALL BIORESOURCES: BUSINESS OVERVIEW 437 FIGURE 1 MICE MODEL MARKET SEGMENTATION 42 FIGURE 2 RESEARCH DESIGN 45 FIGURE 3 MICE MODEL MARKET: BREAKDOWN OF PRIMARIES 47 FIGURE 4 MICE MODEL MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 47 FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024 48 FIGURE 6 ILLUSTRATIVE EXAMPLE OF CHARLES RIVER LABORATORIES: REVENUE SHARE ANALYSIS (2024) 49 FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 50 FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 50 FIGURE 9 MICE MODEL MARKET: CAGR PROJECTIONS 52 FIGURE 10 DATA TRIANGULATION METHODOLOGY 53 FIGURE 11 MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2025 VS. 2030 (USD MILLION) 56 FIGURE 12 MICE MODEL MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 57 FIGURE 13 MICE MODEL MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION) 57 FIGURE 14 MICE MODEL MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 58 FIGURE 15 GEOGRAPHIC SNAPSHOT OF MICE MODEL MARKET 59 FIGURE 16 RISING DEMAND FOR MOUSE CLINICAL TRIALS TO PROPEL MARKET 60 FIGURE 17 MODEL TYPE SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 61 FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 61 FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 62 FIGURE 20 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 62 FIGURE 21 MICE MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63 FIGURE 22 MICE MODEL MARKET: VALUE CHAIN ANALYSIS 75 FIGURE 23 AVERAGE SELLING PRICE TREND OF MODEL TYPES, BY KEY PLAYER, 2022–2024 (USD) 77 FIGURE 24 AVERAGE SELLING PRICE OF MODEL TYPES, BY REGION (USD) 78 FIGURE 25 MICE MODEL MARKET: ECOSYSTEM ANALYSIS 79 FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 86 FIGURE 27 PATENT APPLICATIONS IN MICE MODEL MARKET, JANUARY 2014−DECEMBER 2024 88 FIGURE 28 MICE MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS 103 FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MICE MODEL MARKET 105 FIGURE 30 KEY BUYING CRITERIA FOR END USERS 106 FIGURE 31 INVESTMENT & FUNDING SCENARIO, 2022–2025 107 FIGURE 32 AI-USE CASES IN MICE MODEL MARKET 108 FIGURE 33 NORTH AMERICA: MICE MODEL MARKET SNAPSHOT 225 FIGURE 34 ASIA PACIFIC: MICE MODEL MARKET SNAPSHOT 261 FIGURE 35 REVENUE SHARE ANALYSIS FOR KEY COMPANIES, 2022–2024 (USD MILLION) 328 FIGURE 36 MICE MODEL MARKET SHARE ANALYSIS OF KEY PLAYERS (2024) 329 FIGURE 37 MICE MODEL MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS) 2024, 332 FIGURE 38 MICE MODEL MARKET: COMPANY FOOTPRINT 333 FIGURE 39 MICE MODEL MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 340 FIGURE 40 EV/EBITDA OF KEY VENDORS 343 FIGURE 41 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS 343 FIGURE 42 MICE MODEL MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 344 FIGURE 43 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024) 353 FIGURE 44 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2024) 360 FIGURE 45 INOTIV: COMPANY SNAPSHOT (2024) 370 FIGURE 46 JSR CORPORATION: COMPANY SNAPSHOT (2023) 376 FIGURE 47 BIOCYTOGEN: COMPANY SNAPSHOT (2024) 381 FIGURE 48 SHANGHAI MODEL ORGANISMS CENTER, INC.: COMPANY SNAPSHOT (2024) 387 FIGURE 49 TRANS GENIC INC.: COMPANY SNAPSHOT (2024) 391 FIGURE 50 HARBOUR BIOMED: COMPANY SNAPSHOT (2024) 394 FIGURE 51 GENOWAY: COMPANY SNAPSHOT (2024) 398 FIGURE 52 GEMPHARMATECH: COMPANY SNAPSHOT (2024) 402 FIGURE 53 VIVO BIO TECH LTD.: COMPANY SNAPSHOT (2023) 416 FIGURE 54 CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT (2023) 424

同分類最新報告(醫療與生命科學)

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們